Inclusion Criteria:  Non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs If of reproductive age, willing and able to use a medically highly effective form of birth control 30 days prior to first dose, during the study and for 30 days following last dose of study medication Understands the study procedures in the informed consent form, and be willing and able to comply with the protocol  Exclusion Criteria:  History or presence of clinically significant medical or psychiatric condition or disease History of any illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) A positive test or history of incompletely treated or untreated tuberculosis Donation of > 499 mL of blood or plasma within 56 days of Screening (during a clinical trial or at a blood bank donation) and for 30 days after last dose of study drug